NLRC5 and melanoma: PRMT5 methylates IFN-γ inducible protein 16 (IFI16) and suppresses NLRC5 transcription, inhibiting the cGAS-STING and MHCI pathways in melanoma, thereby weakening IFN signaling and antitumor immune responses.